Univariate and multivariate adjusted OR and 95% CI for regulatory approval of the abstracts reporting CTs according to their study design and characteristics
| Variable . | Univariate OR (95% CI) . | P value . | Multivariate OR (95% CI) . | P value . |
|---|---|---|---|---|
| Number of patients | 1.003 (1.002-1.005) | <.001 | 1.002 (0.999-1.004) | .154 |
| Year | 1.073 (0.889-1.296) | .464 | 0.977 (0.791-1.256) | .978 |
| CT phase | ||||
| Phase 1 | Reference | Reference | ||
| Phase 2 | 1.452 (0.797-2.647) | .223 | 1.405 (0.692-2.856) | .347 |
| Phase 3 | 7.167 (3.246-15.823) | <.001 | 2.843 (0.854-9.470) | .089 |
| Age group | ||||
| Adults (>17 y) | Reference | Reference | ||
| Older adults (>59 y) | 0.321 (0.123-0.836) | .020 | 0.498 (0.159-1.557) | .231 |
| Pediatric | 1.284 (0.396-4.169) | .677 | 0.670 (0.146-3.069) | .606 |
| Type of leukemia | ||||
| AML | Reference | Reference | ||
| ALL | 4.000 (1.788-8.948) | <.001 | 4.999 (1.882-13.282) | .001 |
| CML | 28.333 (9.785-82.039) | <.001 | 21.632 (6.455-72.479) | <.001 |
| CLL | 2.784 (1.427-5.428) | .003 | 2.842 (1.294-6.241) | .009 |
| Disease status | ||||
| Untreated | Reference | Reference | ||
| R and/or R | 0.943 (0.533-1.667) | .839 | 1.442 (0.644-3.230) | .373 |
| Untreated, R and/or R | 0.757 (0.353-1.621) | .473 | 2.655 (0.982-7.172) | .054 |
| No. of authors in the abstract | 1.070 (1.024-1.118) | .003 | 1.043 (0.971-1.121) | .250 |
| No. of institutions involved | 1.064 (1.026-1.104) | <.001 | 0.989 (0.924-1.059) | .756 |
| Multicenter trials | 3.219 (1.416-7.319) | .005 | 1.928 (0.713-5.212) | .196 |
| International study | 3.859 (2.265-6.577) | <.001 | 1.826 (0.888-3.752) | .101 |
| Variable . | Univariate OR (95% CI) . | P value . | Multivariate OR (95% CI) . | P value . |
|---|---|---|---|---|
| Number of patients | 1.003 (1.002-1.005) | <.001 | 1.002 (0.999-1.004) | .154 |
| Year | 1.073 (0.889-1.296) | .464 | 0.977 (0.791-1.256) | .978 |
| CT phase | ||||
| Phase 1 | Reference | Reference | ||
| Phase 2 | 1.452 (0.797-2.647) | .223 | 1.405 (0.692-2.856) | .347 |
| Phase 3 | 7.167 (3.246-15.823) | <.001 | 2.843 (0.854-9.470) | .089 |
| Age group | ||||
| Adults (>17 y) | Reference | Reference | ||
| Older adults (>59 y) | 0.321 (0.123-0.836) | .020 | 0.498 (0.159-1.557) | .231 |
| Pediatric | 1.284 (0.396-4.169) | .677 | 0.670 (0.146-3.069) | .606 |
| Type of leukemia | ||||
| AML | Reference | Reference | ||
| ALL | 4.000 (1.788-8.948) | <.001 | 4.999 (1.882-13.282) | .001 |
| CML | 28.333 (9.785-82.039) | <.001 | 21.632 (6.455-72.479) | <.001 |
| CLL | 2.784 (1.427-5.428) | .003 | 2.842 (1.294-6.241) | .009 |
| Disease status | ||||
| Untreated | Reference | Reference | ||
| R and/or R | 0.943 (0.533-1.667) | .839 | 1.442 (0.644-3.230) | .373 |
| Untreated, R and/or R | 0.757 (0.353-1.621) | .473 | 2.655 (0.982-7.172) | .054 |
| No. of authors in the abstract | 1.070 (1.024-1.118) | .003 | 1.043 (0.971-1.121) | .250 |
| No. of institutions involved | 1.064 (1.026-1.104) | <.001 | 0.989 (0.924-1.059) | .756 |
| Multicenter trials | 3.219 (1.416-7.319) | .005 | 1.928 (0.713-5.212) | .196 |
| International study | 3.859 (2.265-6.577) | <.001 | 1.826 (0.888-3.752) | .101 |
Bold values indicate statistical significance.
ALL, acute lymphocytic leukemia; CI, confidence interval; CLL, chronic lymphocytic leukemia; OR, odds ratio; R and/or R, relapsed and/or refractory.